GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the Medicine missed the key goal
GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the Medicine missed the key goal in a late-stage clinical study; said the drug, camlipixant, achieved mixed results in two trials--with one hitting the primary objective of significant reductions in cough frequenc